Sign in
Not yet recruitingPhase 4

Low-dose Versus Standard-dose Remimazolam for Prevention of Emergence Agitation After Nasal Surgery

Key facts

Who runs it
Jeju National University School of Medicine
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
138 people, planned
Started
24 Jul 2026
Expected to end
31 Jul 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Remimazolam
Record updated
31 July 2026

Who can take part

Age
18 years to 79 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults aged 18 to 79 years
  • Scheduled to undergo elective nasal surgery under sevoflurane-based general anesthesia at Jeju National University Hospital
  • Able to provide written informed consent

Who cannot take part

  • History of allergy or hypersensitivity to benzodiazepines
  • Inability to provide informed consent due to cognitive impairment
  • Preexisting psychiatric disorders
  • History of alcohol or substance abuse
  • Contraindications to remimazolam
  • Inability to assess the Riker Sedation-Agitation Scale (SAS)
  • Body mass index (BMI) > 40 kg/m²

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Emergence agitation (EA) is a common complication during recovery from sevoflurane anesthesia, particularly after nasal surgery. Although remimazolam 0.1 mg/kg has been shown to reduce the incidence of EA, this dose may produce excessive sedation and increase the risk of intraoperative burst suppression.

Read full original descriptionShow less

This randomized, double-blind, non-inferiority trial will compare low-dose remimazolam (0.03 mg/kg) with the standard dose (0.1 mg/kg) administered at the end of surgery in adult patients undergoing nasal surgery under sevoflurane anesthesia. The primary objective is to determine whether low-dose remimazolam is non-inferior to the standard dose in preventing emergence agitation. Secondary outcomes include burst suppression, recovery profiles, and safety outcomes.

The 2 groups in the trial

  • Standard-dose RemimazolamTreatment being tested

    Participants will receive remimazolam 0.1 mg/kg intravenously immediately after discontinuation of sevoflurane at the end of nasal surgery under general anesthesia.

    Treatment: Remimazolam

  • Low-dose RemimazolamTreatment being tested

    Participants will receive remimazolam 0.03 mg/kg intravenously immediately after discontinuation of sevoflurane at the end of nasal surgery under general anesthesia.

    Treatment: Remimazolam

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Low-dose Versus Standard-dose Remimazolam for Prevention of Emergence Agitation After Nasal Surgery Under Sevoflurane Anesthesia: A Randomized Double-blind Non-inferiority Trial
Criteria questions
Built from NCT07740655, who can take part
Record updated
31 July 2026